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Aims Late acquired incomplete stent apposition (ISA) is more common after drug-eluting stent (DES) than bare metal stent
(BMS) implantation and has been associated with vascular hypersensitivity and stent thrombosis (ST). We investigated
the impact of incidentally discovered ISA as assessed by intravascular ultrasound (IVUS) 8 months after DES implant-
ation on the long-term clinical outcome.
Methods
and results
A total of 194 patients with 221 lesions were prospectively followed through 5 years. At 8 months, IVUS showed
evidence of ISA among 37 patients with 39 lesions (18%) (mean ISAmax 4.7+ 5.0 mm
2), whereas no ISA was
observed among 157 patients with 182 lesions. Incomplete stent apposition was more prevalent among segments
treated with sirolimus-eluting (n ¼ 103) than paclitaxel-eluting stents (n ¼ 118) (27 vs. 9%, P ¼ 0.001). Between
IVUS investigation at the 8-month and 5-year follow-up, major adverse cardiac events occurred more frequently
in patients with (18.9%, n ¼ 7) than without ISA (7.0%, n ¼ 11) (HR ¼ 2.71, 95% CI: 1.05–6.96, P ¼ 0.031). While
there were no differences with respect to death, the rate of myocardial infarction was higher among patients with
(13.5%, n ¼ 5) than without ISA (1.9%, n ¼ 3) (HR ¼ 7.53, 95% CI: 1.79–31.6, P ¼ 0.001). Very late ST was more
common among patients with than without ISA [Academic Research Consortium-deﬁnite ST:13.5% (n ¼ 5) vs.
0.6% (n ¼ 1) HR ¼ 23.2, 95% CI: 2.65–203, P, 0.001].
Conclusion In the present study, the presence of ISA as assessed by IVUS 8 months after DES implantation was associated with a
higher rate of myocardial infarction and very late stent thrombosis during long-term follow-up. The prognostic impact
of ISA on long-term clinical outcomes requires further investigation.
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Introduction
Incomplete stent apposition (ISA) is a morphological feature
assessed by intravascular imaging, such as intravascular ultrasound
(IVUS), or optical coherence tomography and describes the lack of
contact between stent struts and the adjacent arterial wall. The
timing of intravascular imaging relative to the index procedure
allows to distinguish between post-procedural, persistent, and
late acquired phenotypes. Incomplete stent apposition assessed
by IVUS has been reported in up to one-third of treated segments
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after drug-eluting stents (DES) implantation,1 and has been related
to various causes such as inhomogeneous stent expansion at the
time of stent implantation, dissolution of thrombus behind stent
struts in the setting of acute myocardial infarction (MI), chronic
stent recoil, or positive arterial remodelling with an increase in
the external elastic membrane (EEM) out of proportion to the
increase in peri-stent plaque and media.2,3 The latter phenomenon
may be of particular importance in patients treated with DES.
An exceedingly high incidence of ISA (.75%) has been
observed among patients presenting with very late stent throm-
bosis (ST).3–5 In addition, the extent of positive vessel remodelling
associated with ISA among patients suffering from very late ST has
been correlated with the amount of inﬂammatory inﬁltrates at the
vicinity of stent struts, suggesting an underlying vascular toxicity in
the pathogenesis of very late ST. Conversely, the clinical impact of
incidentally discovered ISA in otherwise asymptomatic patients
is debated. Late acquired ISA has been reported in 2–5% of
segments after bare metal stent (BMS)6,7 and in 7–21% after
DES implantation,8,9 and several studies failed to observe untoward
adverse events related to ISA.8–14 However, these studies were
limited by small patient populations and a short follow-up duration,
prohibiting ﬁrm conclusions. The aim of the present study was
therefore to investigate the long-term clinical outcome up to
5 years among patients with compared with those without ISA
as assessed by IVUS 8 months after DES implantation.
Methods
Patient population
Patients of the present study constitute a subpopulation of the SIRTAX
trial.15 In this prospective, single blind, randomized trial, 1012 patients
were treated with either sirolimus-eluting (SES) (Cypher and
Cypher Select, Cordis, Miami Lakes, Florida) (503 patients), or
paclitaxel-eluting stents (PES) (Taxus Express 2, Boston Scientiﬁc
Corp., Natick, Massachusetts) (509 patients). Of the overall SIRTAX
trial population, 540 patients underwent repeat angiography at 8
months. The ﬁrst 234 patients (323 segments) of the angiographic
follow-up cohort also underwent IVUS investigation (Figure 1). After
exclusion of 38 patients (50 segments) from the IVUS image analysis
due to failed acquisition, inadequate pullback, or poor image quality,
IVUS analysis at 8 months was possible in 196 patients (223 segments).
For the purpose of the current analysis, two patients who suffered
from ST between the time of stent implantation and IVUS investigation
at 8-month follow-up were excluded from the analysis. The remaining
194 patients (free of MI at 8 months) with 221 DES segments consti-
tute the patient population with a landmark analysis of clinical outcome
between 8 months after DES implantation (time point of IVUS investi-
gation) and 5 years of follow-up. We compared the baseline character-
istics and clinical outcome between patients with and without IVUS
investigation at 8 months, and between patients with and without
ISA. Of note, IVUS imaging was not performed at baseline but only
at the time of angiographic follow-up precluding the differentiation
between persistent and late acquired ISA. The institutional review
board of both participating institutions approved the study. All patients
provided written informed consent. The study complied with the
declaration of Helsinki regarding investigations in humans and was
approved by the Ethics Committees at the Bern University Hospital
and University Hospital Zurich, both in Switzerland.
Quantitative coronary angiographic analysis
Coronary angiograms were digitally recorded at baseline, immediately
after the procedure, and at follow-up and analysed by personnel
unaware of the type of the implanted stent. Digital angiograms were
analysed with the use of an automated edge-detection system
(CAAS II, Pie Medical Imaging). Quantitative measurements included
the diameter of the reference vessel, the minimal luminal diameter,
and per cent diameter stenosis (deﬁned as the diameter of the
reference vessel minus the minimal luminal diameter, divided by the
reference diameter and multiplied by 100).
Figure 1 Flow chart of study population. ISA, incomplete stent apposition; IVUS, intravascular ultrasound.
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Intravascular ultrasound image acquisition
and analysis
The protocol sequence to obtain IVUS imaging at the 8-month follow-
up has been previously described in detail.3 Brieﬂy, the IVUS catheter
(Eagle Eyew scanner, Volcano Therapeutics, Inc.) was positioned
.10 mm beyond the distal edge of the study stent and was withdrawn
using a motorized pullback (0.5 mm/s). Quantitative IVUS analyses
were performed off-line according to the criteria of the clinical
expert consensus document on IVUS using computerized planimetry
(In-Vision Vieww 1.0, Medimatic, Inc.).16 Quantitative measures
included the EEM, lumen, and stent cross-sectional area (CSA) at
stented and reference segments. The image slice with the smallest
stent and lumen CSA, and the image slice with the greatest EEM
were also analysed. The proximal and distal reference segments
selected for the analysis were the most normal-appearing cross-
sections within 10 mm proximal or distal to the lesion but before
any side branch. Incomplete stent apposition was deﬁned as lack of
contact between at least one strut and the underlying arterial wall
intima that did not overlap a side branch with evidence of blood
ﬂow behind the strut. The length of the ISA site was measured from
multiple longitudinal views. When the patient had ISA sites separated
from each other by areas of completely apposed stented segments, the
total length of the ISA was deﬁned as the sum of the lengths of each
ISA segment. In the segment with ISA, the lumen contours were deli-
neated within and outside the stent strut boundaries.17 Within the ISA
segment, stent and lumen CSA were measured every 0.5 mm.
Study endpoints and deﬁnitions
All patients were prospectively followed per protocol at 1, 6, and 9
months, and 1, 2, 3, 4, and 5 years after stent implantation. An inde-
pendent clinical events committee blinded to treatment assignment
and IVUS ﬁndings adjudicated all endpoints. Major adverse cardiac
events (MACEs) were deﬁned as the composite of cardiac death, MI,
or clinically driven target lesion revascularization (TLR). Target lesion
revascularization and target vessel revascularization (TVR) were con-
sidered to be clinically driven if the stenosis of the target lesion or
vessel was .50% on the basis of quantitative coronary angiography
in the presence of ischaemic signs or symptoms, or if there was a sten-
osis of .70% in the absence of ischaemic signs or symptoms. Target
lesion revascularization was deﬁned as a repeated revascularization
based on a stenosis within the stent or within the 5-mm borders prox-
imal or distal to the stent. The diagnosis of MI after the intervention
was established whenever new Q-waves of at least 0.4 s duration in
at least two contiguous leads appeared on the electrocardiogram
with an elevated creatine kinase MB fraction level, or in the absence
of pathological Q-waves, an elevation in creatine kinase levels to
more than twice the upper limit of normal with an elevated creatine
kinase MB or troponin I level. Deﬁnite ST fulﬁlled the Academic Re-
search Consortium (ARC)18 criteria and was deﬁned as an acute cor-
onary syndrome with angiographic documentation of either target
vessel occlusion or thrombus within or adjacent to the previously suc-
cessfully stented segment.
Statistical analysis
Normally distributed variables were analysed using parametric tests
and non-normally distributed data using non-parametric tests. Con-
tinuous variables are expressed as mean+ standard deviation and dif-
ferences were compared using Student’s t test or Mann–Whitney U
test. Categorical variables are expressed as counts and percentages
and differences were assessed by the Fisher exact test or x2 test, as
appropriate. The comparison between the groups were carried out
using a mixed model and P-values are derived using maximum likeli-
hood logistic and linear-regression models based on robust standard
errors that allow for the correlation of multiple lesions within patients.
Event-free survival was analysed with the Kaplan–Meier method, and
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Table 1 Baseline clinical characteristics among non-intravascular ultrasound participants and intravascular ultrasound
participants in the SIRTAX study, and among patients with and without incomplete stent apposition in the intravascular
ultrasound study
SIRTAX study (n5 972) IVUS study (n 5 194)
Patients IVUS (n5 194) Non-IVUS (n5 778) P-value ISA (n 5 37) Non-ISA (n5 157) P-value
Age, mean+ SD 59.5+ 10.4 62.9+ 11.2 0.001 58.0+ 9.3 59.9+ 10.6 0.32
Male [n (%)] 159 (82.0) 587 (75.5) 0.055 30 (81.1) 129 (82.2) 0.88
Hypertension [n (%)] 105 (54.1) 493 (63.4) 0.018 16 (43.2) 89 (56.7) 0.14
Current smoking [n (%)] 81 (41.8) 274 (35.2) 0.091 20 (54.1) 61 (38.9) 0.09
Diabetes mellitus [n (%)] 32 (16.5) 163 (21.0) 0.17 5 (13.5) 27 (17.2) 0.59
Dyslipidaemia [n (%)] 119 (61.3) 453 (58.2) 0.43 24 (64.9) 95 (60.5) 0.62
Family history of CAD [n (%)] 78 (39.8) 295 (37.9) 0.63 16 (43.2) 61 (38.9) 0.62
Indication at baseline [n (%)] 0.27 0.72
Stable angina pectoris 104 (53.6) 364 (46.8) 18 (48.6) 86 (54.8)
ACS—STEMI 42 (21.7) 180 (23.1) 10 (27.0) 32 (20.4)
ACS—NSTEMI 41 (21.1) 186 (23.9)
Unstable 7 (3.6) 48 (6.2) 7 (18.9) 34 (21.7)
Multivessel disease [n (%)] 118 (60.8) 459 (59.0) 0.64 24 (64.9) 94 (59.9) 0.58
LVEF, mean%+ SD 58.3+ 10.3 56.3+ 12.1 0.029 57.1+ 9.5 58.6+ 10.5 0.41
ACS, acute coronary syndrome; CAD, coronary artery disease; IVUS, intravascular ultrasound study; LVEF, left ventricular ejection fraction; (N-) STEMI, (non-)ST-segment
elevation myocardial infarction; SD, standard deviation.
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the corresponding probability value was obtained from a log-rank test.
The Mantel–Cox method was used to estimate hazard ratios and 95%
conﬁdence intervals for comparisons of clinical outcomes between
groups and the log-rank test to calculate corresponding P-values. No
adjustments were made for multiple comparisons in secondary ana-
lyses; P-values are two-sided; the signiﬁcance level was set at 0.05. Ana-
lyses were performed in STATA (Stata, Inc., College Station, TX, USA).
Results
Baseline clinical, angiographic,
and procedural characteristics
Baseline clinical and angiographic characteristics of patients under-
going IVUS at 8 months and those not undergoing IVUS are
summarized in Table 1. Compared with patients not undergoing
IVUS, those undergoing IVUS were younger (59.5+ 10.4 vs.
62.9+11.2 years, P ¼ 0.001), more frequently male (82.0 vs.
75.5%, P ¼ 0.055), less frequently hypertensive (54.1 vs. 63.4%,
P ¼ 0.018), and had better left ventricular function (58.3+10.3
vs. 56.3+12.1%, P ¼ 0.029). A total of 194 patients with 221
segments treated with 103 SES and 118 PES underwent IVUS 8
months after DES implantation. Among patients undergoing IVUS,
baseline angiographic variables were well balanced between SES
and PES. Lesion length amounted to 12.9+6.8 and 14.2+
8.4 mm in SES- and PES-treated segments, respectively (P ¼ 0.24),
and reference vessel diameter was 2.81+0.43 and 2.83+
0.44 mm, respectively (P ¼ 0.25). Stent length (SES: 18.5+8.5 mm
vs. PES: 19.1+10.1 mm, P ¼ 0.64) and stent diameter (SES:
2.93+0.32 mm vs. PES: 2.97+0.34 mm, P ¼ 0.32) were similar
for both groups. Maximal implantation pressure was slightly higher
in the SES group (14.1+2.6 vs. 13.4+2.7 atm, P ¼ 0.21).
Intravascular ultrasound findings
at 8-month follow-up
Incomplete stent apposition was documented in 39 segments (18%
of stented segments) of 37 patients at the 8-month IVUS investiga-
tion and constitutes the ISA group. One hundred ﬁfty-seven
patients with 182 segments showed no evidence of ISA (non-ISA
group). Baseline clinical characteristics were similar for patients
with or without ISA (Table 1). Of note, there was no difference
with respect to age, diabetes mellitus, dyslipidaemia, and acute
coronary syndrome as indication for the index procedure. While
baseline angiographic characteristics were comparable for patients
with or without ISA, stent length was longer in patients with than
without ISA (22.1+ 11.6 vs. 18.1+8.7 mm, P ¼ 0.048) (Table 2).
Intravascular ultrasound data at 8 months are summarized in
Table 3. We observed no difference in terms of reference vessel
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Table 2 Baseline angiographic and procedural
characteristics in segments with and without
incomplete stent apposition
Segments ISA
(n 5 39)
Non-ISA
(n5 182)
P-value
Target vessel, n (%) 0.68
Left anterior descending
artery
15 (39) 81 (45)
Right coronary artery 14 (36) 63 (35)
Left circumﬂex artery 10 (26) 38 (21)
Before procedure
Lesion length, mm+ SD 13.6+ 6.4 13.4+ 7.3 0.88
RVD, mm+ SD 2.82+ 0.42 2.86+ 0.44 0.61
MLD, mm+ SD 0.35+ 0.38 0.48+ 0.42 0.043
Stenosis, %+ SD 87.1+ 14.3 83.3+ 13.5 0.12
During procedure
Type of stent, n (%) 0.001
SES 28 (72) 75 (41)
PES 11 (28) 107 (59)
Stent diameter, mm
+ SD
2.95+ 0.30 2.96+ 0.34 0.82
Stent length, mm+ SD 22.1+ 11.6 18.1+ 8.7 0.048
Maximal balloon
pressure, atm+ SD
13.8+ 2.9 14.2+ 2.6 0.48
Maximal balloon
diameter/RVD
(balloon to artery
ratio), mean+ SD
1.12+ 0.15 1.13+ 0.20 0.27
ISA, incomplete stent apposition; MLD, minimal lumen diameter; PES,
paclitaxel-eluting stent; RVD, reference vessel diameter; SD, standard deviation;
SES, sirolimus-eluting stent. P-values were derived using maximum-likelihood
logistic and linear-regression models based on robust standards errors that
allowed for the correlation of multiple segments within a patient.
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Table 3 Intravascular ultrasound measurements at
8 months
Segments ISA
(n5 39)
Non-ISA
(n5 182)
P-value
Reference segment
EEM-CSA, mm2+ SD 15.3+ 4.7 14.4+ 4.7 0.29
Lumen-CSA, mm2+ SD 9.6+ 3.7 8.0+ 2.8 0.015
Stent segment
EEM-CSA, mm2+ SD 17.1+ 4.6 15.8+ 4.6 0.14
Stent-CSA, mm2+ SD 6.9+ 1.4 6.9+ 2.0 0.83
Minimum Stent-CSA,
mm2+ SD
6.2+ 1.4 6.1+ 1.9 0.86
Minimum Stent-CSA
,5 mm2, n (%)
4 (10.3) 44 (24.2) 0.061
Stent expansion +SD 0.7+ 0.2 0.8+ 0.2 0.001
Remodelling index +SD 1.3+ 0.3 1.3+ 0.7 0.68
In-stent lumen-CSA, mm2
+SD
6.9+ 1.4 6.7+ 1.9 0.50
NIH, mm2 +SD 0.1+ 0.2 0.2+ 0.5 0.004
Percentage of stent volume
obstruction, % +SD
1.3+ 2.3 2.8+ 5.0 0.004
CSA, cross-sectional area; EEM, external elastic membrane; ISA, incomplete stent
apposition; NIH, neointimal hyperplasia; SD, standard deviation. P-values were
derived using maximum-likelihood logistic and linear-regression models based on
robust standards errors that allowed for the correlation of multiple segments
within a patient.
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and stented segment CSA, whereas patients with ISA showed a
lower degree of stent expansion (0.7+0.2 vs. 0.8+0.2, P ¼
0.001) (Table 3). Incomplete stent apposition was longer and
three times more frequent in SES- than PES-treated segments
(Table 4). Similarly, stent-CSA (PES: 7.3+1.9 vs. SES: 6.4+
1.8 mm2, P ¼ 0.001) and stent expansion index (PES: 0.87+0.21
vs. SES: 0.77+0.19, P ¼ 0.002) were lower for SES- than
PES-treated segments.
Clinical outcomes
The long-term clinical outcomes through 5 years of patients with
and without IVUS investigation at 8 months as well as of patients
with and without ISA dare summarized in Table 5. Compared with
patients who did not undergo IVUS at 8 months, those with IVUS
had a lower rate of MACE (12.4 vs. 21.9%, HR ¼ 0.53, 95% CI:
0.34–0.81, P ¼ 0.003), cardiac death (1.0 vs. 7.1%, HR ¼ 0.14, 95%
CI: 0.03–0.57, P ¼ 0.001) and a trend towards fewer MIs (4.1 vs.
7.2%, HR ¼ 0.47, 95% CI: 0.26–1.14, P ¼ 0.10), but a similar risk
of deﬁnite ST (3.1 vs. 4.5%,HR ¼ 0.65, 95%CI: 0.27–1.56, P ¼ 0.33).
At 5 years of follow-up, 24 patients (12.4%) of the overall IVUS
group had suffered from at least one MACE event. There were no
signiﬁcant differences regarding overall mortality, cardiac death,
TLR, TVR, and MACE among patients with or without ISA.
However, MI was more common among patients with than
without ISA (13.5 vs. 1.9%, HR ¼ 7.53, 95% CI: 1.79–31.6, P ¼
0.001). Figure 2 shows the cumulative frequency of MACE and
the composite of cardiac death or MI up to 5 years. In terms of
cardiac death or MI, we did not observe any difference between
patients with and without ISA up to 2 years of follow-up.
However, event curves did separate beyond 2 years and continued
to diverge up to 5 years in disfavour of patients with ISA. The
increased rate of MI was directly related to an increased rate of
very late ST in patients with ISA when compared with those
without ISA (ARC-deﬁnite ST: 13.5 vs. 0.6%, HR ¼ 23.2, 95% CI:
2.65–203, P, 0.001). We observed no signiﬁcant difference in
the rate of ST between the two stent types [SES 4 (4.4%) when
compared with PES 2 (1.9%), HR ¼ 0.44 95% CI: 0.08–2.43, P ¼
0.34]. Figure 3 demonstrates examples of patients with incidental
ISA documented at the 8-month follow-up suffering from very
late ST during the subsequent clinical follow-up period.
Discussion
The present study with the longest reported follow-up of patients
with incidentally discovered ISA has the following principal ﬁndings:
(1) Compared with the unselected all-comer patient population
included into the SIRTAX trial, patients enrolled in the IVUS
substudy had a lower cardiovascular risk proﬁle and conse-
quently showed a lower risk of MACE during extended clinical
follow-up.
(2) The presence of ISA as detected by IVUS at 8 months after
DES implantation is associated with an impaired clinical
outcome. The increased risk of death or MI was directly
related to the increased risk of very late ST.
Selection bias of patients included into
the intravascular ultrasound substudy
Enrollment into the IVUS substudy was limited to the ﬁrst 234
patients included into the SIRTAX trial returning for follow-up
angiography at 8 months. This resulted in a selection bias
towards the inclusion of lower risk patients compared with the
overall study population. This phenomenon has been previously
observed in some19,20 but not all9,21,22 IVUS studies and has
been related to the omission of IVUS among patients with severely
obstructive vessels and among patients with MACE.
Incidence of incomplete stent apposition
Incomplete stent apposition was found in 18% of the patients in
the current analysis and was particularly frequent (approximately
one-quarter) among patients treated with SES, a ﬁnding that is con-
sistent with previous reports. In the RAVEL study, 21% of SES-
treated segments showed evidence of ISA.9 In a pooled analysis
of 180 SES included into RAVEL, e-SIRIUS, and SIRIUS, Hoffmann
et al.23 reported a 25% incidence of ISA after SES implantation.
The incidence of ISA 6–9 months after implantation of PES has
been reported to range from 4.4 to 8.0% in the TAXUS-II and
-IV trials.14,24,25 One possible explanation of an increased incidence
of ISA in SES-compared with PES-treated segments may be the
lower reported rate of late loss in SES compared with PES. The
other possible explanation may be related to inhomogeneous
stent expansion at the time of stent implantation or chronic
recoil. Thus, we observed smaller stent-CSA, stent expansion
index and in-stent lumen-CSA with SES than PES despite a
similar stent diameter and a somewhat higher implantation pres-
sure with SES. These ﬁndings are consistent with data previously
reported by Cheneau et al.25
Incomplete stent apposition and stent
thrombosis
Very late ST after coronary stent implantation is a complex and
multifactorial process. Incomplete stent apposition has been
associated with delayed endothelial healing and drug-induced
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 4 Incomplete stent apposition in
paclitaxel-eluting stents and sirolimus-eluting stents
Segments All
(n 5 221)
PES
(n5 103)
SES
(n5 118)
P-value
ISA, n (%) 39 (18%) 11 (9%) 28 (27%) 0.001
ISAmax-CSA, mm
2 4.6+ 5.0 5.0+ 5.1 4.5+ 5.0 0.90
Total ISA length, mm 1.9+ 1.4 1.0+ 0.9 2.3+ 1.4 0.003
Maximal ISA depth,
mm
0.8+ 0.5 0.8+ 0.6 0.8+ 0.4 0.89
Maximal ISA angle, 8 114+ 60 92+ 42 120+ 63 0.076
Coronary aneurysm,
n (%)
2 (1%) 0 (0%) 2 (2%) 0.57
CSA, cross-sectional area; ISA, incomplete stent apposition; ISAmax-CSA, maximal
ISA-CSA; PES, paclitaxel-eluting stent; SES, sirolimus-eluting stent. P-values were
derived using maximum-likelihood logistic and linear-regression models based on
robust standards errors that allowed for the correlation of multiple lesions within
a patient. P-value for coronary aneurysm is based on Fisher’s exact test.
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hypersensitivity reactions with exaggerated positive vessel remod-
elling. The impact of ISA on the long-term clinical outcome has
been the subject of debate since its initial description.26 Several
studies have used IVUS to describe morphological changes of
arterial structure among patients presenting with very late ST.
Feres et al.27 and two previous reports from our group3,4 found
an exceedingly high rate of ISA among patients presenting with
very late ST. In these patients, ISA was not only found to be
much more frequent but also characterized by a larger CSA with
evidence of vessel remodelling. The correlation between the
extent of inﬂammatory inﬁltrates as obtained from thrombus aspi-
rates and evidence of vessel remodelling by IVUS suggested a link
between the presence of ISA and the pathogenesis of very late ST.28
In contrast, ISA as incidentally observed during routine IVUS
investigation in asymptomatic patients may be related to various
causes such as inhomogeneous stent expansion, dissolution of
thrombus behind the stent struts or stent recoil, and its impact
on the clinical outcome remains incompletely understood.2,3
Several previous reports failed to demonstrate a signiﬁcant
adverse effect of ISA on the clinical outcome during short- to
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Table 5 Clinical outcomes
IVUS Non-IVUS HR (95% CI) P-value ISA Non-ISA HR (95% CI) P-value
No. of patients 194 778 37 157
From stent implantation to IVUS investigation at 8 months
Death 0 (0) 15 (1.9) 0.13 (0.01–2.11) 0.052 0 (0) 0 (0) —
Cardiac death 0 (0) 10 (1.3) 0.19 (0.01–3.20) 0.23 0 (0) 0 (0) —
MI 0 (0) 29 (3.7) 0.07 (0.00–1.06) 0.003 0 (0) 0 (0) —
Death or MI 0 (0) 42 (5.4) 0.04 (0.00–0.72) ,0.001 0 (0) 0 (0) —
Clinically driven TLR 6 (3.1) 46 (5.9) 0.51 (0.22–1.19) 0.11 0 (0) 6 (3.8) 0.31 (0.02–5.40) 0.60
Clinically driven TVR 7 (3.6) 52 (6.7) 0.52 (0.24–1.15) 0.10 0 (0) 7 (4.5) 0.27 (0.02–4.58) 0.35
MACE 6 (3.1) 63 (8.1) 0.37 (0.16–0.85) 0.015 0 (0) 6 (3.8) 0.31 (0.02–5.40) 0.60
From stent implantation to 5 years
Death 3 (1.5) 97 (12.5) 0.12 (0.04–0.37) ,0.001 0 (0) 3 (1.9) 0.59 (0.03–11.2) 1.00
Cardiac death 2 (1.0) 55 (7.1) 0.14 (0.03–0.57) 0.001 0 (0) 2 (1.3) 0.83 (0.04–16.9) 1.00
MI 8 (4.1) 56 (7.2) 0.54 (0.26–1.14) 0.10 5 (13.5) 3 (1.9) 7.53 (1.79–31.6) 0.001
Death or MI 11 (5.7) 144 (18.5) 0.29 (0.15–0.53) ,0.001 5 (13.5) 6 (3.8) 3.75 (1.14–12.3) 0.019
Clinically driven TLR 19 (9.8) 111 (14.3) 0.64 (0.40–1.05) 0.07 6 (16.2) 13 (8.3) 1.94 (0.74–5.09) 0.17
Clinically driven TVR 27 (13.9) 133 (17.1) 0.76 (0.50–1.15) 0.20 7 (18.9) 20 (12.7) 1.48 (0.63–3.50) 0.37
MACE 24 (12.4) 170 (21.9) 0.53 (0.34–0.81) 0.003 7 (18.9) 17 (10.8) 1.75 (0.73–4.20) 0.21
From IVUS investigation to 5 years
Death 3 (1.5) 82 (10.5) 0.14 (0.04–0.44) ,0.001 0 (0) 3 (1.9) 0.59 (0.03–11.2) 1.00
Cardiac death 2 (1.0) 45 (5.8) 0.17 (0.04–0.70) 0.005 0 (0) 2 (1.3) 0.83 (0.04–16.9) 1.00
MI 8 (4.1) 27 (3.5) 1.09 (0.50–2.41) 0.82 5 (13.5) 3 (1.9) 7.53 (1.79–31.6) 0.001
Death or MI 11 (5.7) 102 (13.1) 0.40 (0.21–0.74) 0.003 5 (13.5) 6 (3.8) 3.75 (1.14–12.3) 0.019
Clinically driven TLR 13 (6.7) 65 (8.4) 0.74 (0.41–1.34) 0.31 6 (16.2) 7 (4.5) 3.60 (1.22–10.7) 0.013
Clinically driven TVR 20 (10.3) 81 (10.4) 0.91 (0.56–148) 0.71 7 (18.9) 13 (8.3) 2.28 (0.91–5.73) 0.07
MACE 18 (9.3) 107 (13.8) 0.61 (0.37–1.01) 0.053 7 (18.9) 11 (7.0) 2.71 (1.05–6.96) 0.031
ARC-deﬁnite stent thrombosis
Early 0 (0) 15 (1.9) 0.13 (0.01–2.11) 0.052 0 (0) 0 (0) —
Late 0 (0) 3 (0.4) 0.57 (0.03–11.0) 1.0 0 (0) 0 (0) —
Very late 6 (3.1) 17 (2.3) 1.31 (0.52–3.33) 0.57 5 (13.5) 1 (0.6) 23.2 (2.65–203) ,0.001
Overall 6 (3.1) 35 (4.5) 0.65 (0.27–1.56) 0.33 5 (13.5) 1 (0.6) 23.2 (2.65–203) ,0.001
ARC-deﬁnite or probable stent thrombosis
Early 0 (0) 16 (2.1) 0.12 (0.01–1.97) 0.053 0 (0) 0 (0) —
Late 0 (0) 3 (0.4) 0.57 (0.03–11.0) 1.0 0 (0) 0 (0) —
Very late 7 (3.7) 17 (2.3) 1.53 (0.64–3.70) 0.34 5 (13.5) 2 (1.3) 11.6 (2.21–60.6) 0.0002
Overall 7 (3.6) 36 (4.7) 0.74 (0.33–1.67) 0.47 5 (13.5) 2 (1.3) 11.6 (2.21–60.6) 0.0002
ARC, Academic Research Consortium; ISA, incomplete stent apposition; MACE, Major adverse clinical events: cardiac death, myocardial infarction and TLR, target-lesion
revascularization; TVR, target-vessel revascularization. HR, hazard ratios using the Mantel–Cox method. Relative risks were calculated after a continuity correction of 0.5 when
one of the cell sizes was zero; P-values are from two-sided Fisher’s exact test.
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mid-term follow-up up to 12 months.8,10,14,17,29 However, ISA may
affect the clinical course only during longer-term follow-up
especially as it relates to the incidence of very late ST. Three
studies suggest an association between the observed presence of
ISA and subsequent adverse events during long-term examination
up to 4 years. Hoffmann et al.23 found ISA in 45 of 180 SES seg-
ments and in 12 of 145 BMS segments at 6–8 months IVUS follow-
up. Although the authors observed no difference in MACE, the
rate of MI was signiﬁcantly higher among patients with ISA than
without ISA (16 vs. 5%, P ¼ 0.02). Moreover, the only single very
late ST event occurred in the ISA group (P ¼ NS). Qian et al.30
discovered ISA in 13 of 76 patients (17%) at 6 months after DES
implantation. At 34+ 5-month follow-up, 3 of 13 patients (23%)
with ISA suffered from very late ST, MI, and TLR, and one
patient died during the hospitalization. In a study of 195 patients
investigated with IVUS at baseline and at 6–8-month follow-up,
Siqueira et al.5 reported the clinical outcome of 13 patients
(6.7%) with persistent ISA and 10 patients (5.1%) with late
acquired ISA during a mean follow-up of 29+15 months. Patients
with late acquired ISA were signiﬁcantly more prone to very late
ST (20 vs. 0%, P ¼ 0.002), TLR (20 vs. 0.6%, P ¼ 0.007), and MI
(20 vs. 0%, P ¼ 0.002) than patients without ISA (n ¼ 172) in
this study. Finally, a meta-analysis of 17 trials showed an increased
risk of ST in patients with late acquired ISA compared with those
without ISA (odds ratio: 6.51, 95% CI: 1.34–34.91, P ¼ 0.02).31
Incomplete stent apposition
and restenosis
We found no signiﬁcant difference regarding the risk for revascu-
larization and MACE between patients with or without ISA. This
is likely explained by the fact that the increased rate of ST in the
ISA group was balanced by more frequent revascularization
procedures in the non-ISA group. This ﬁnding is in line with
reports from Hong et al.8 and Kimura et al.29 who observed less
intimal hyperplasia in the presence of ISA.
Study limitations
Several limitations require consideration when interpreting the
results of the present study. The most important limitation is the
lack of a reference IVUS examination at baseline, which precludes
any conclusion regarding the cause of ISA found at IVUS follow-up,
particularly as it relates to the assessment of late acquired ISA.
Moreover, it should be acknowledged that the number of patients
included into this IVUS study is relatively small and therefore
underpowered to evaluate safety endpoints and predictors of
ISA. In addition, the patients who underwent an 8-month IVUS
investigation were at lower risk compared with patients who did
not undergo an 8-month IVUS investigation in the SIRTAX trial.
Nevertheless, we observed more frequent clinical events in
patients with ISA than without ISA. Finally, ISA has been delineated
Figure 2 Kaplan–Meier cumulative event curves (%) for patients with (black line) and without (dashed line) incomplete stent apposition. The
vertical dashed line marks the 8-month intravascular ultrasound study. (A) Major adverse clinical events: cardiac death, myocardial infarction, and
target-lesion revascularization. (B) Myocardial infarction or cardiac death. (C) Deﬁnite stent thrombosis. IVUS, intravascular ultrasound; ISA,
incomplete stent apposition; PCI, percutaneous coronary intervention.
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Figure 3 Examples of very late ST in patients with incidental incomplete stent apposition documented at 8-month angiographic follow-up. (A)
Angiographic and (B) intravascular ultrasound ﬁndings at the 8-month follow-up (C ) angiographic ﬁndings before, (D) during and (E) at the end
of the revascularization procedure at the time of very late ST. (A) Angiographic and intravascular ultrasound ﬁndings 8 months after primary PCI
with implantation of paclitaxel-eluting stent in the right coronary artery of a 53-year-old male treated for acute inferior ST-elevation MI. The
clinical follow-up was complicated by very late ST 34 months after the index procedure (26 months after angiographic follow-up). (B) Angio-
graphic and intravascular ultrasound ﬁndings 8-month after PCI with implantation of sirolimus-eluting stunt in the left anterior descending artery
of a 43-year-old male treated for a non-ST elevation MI. The clinical follow-up was complicated by very late ST 43 months after the index
procedure (35 months after angiographic follow-up). EEM, external elastic membrane; IVUS, intravascular ultrasound; PES, paclitaxel-eluting
stent; SES, sirolimus-eluting stent; ST, stent thrombosis.
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using IVUS, and the use of new intravascular imaging techniques
with superior resolution may provide more insight into the
morphology and clinical sequelae of ISA.
Conclusion
In the present study, the presence of ISA as assessed by IVUS 8
months after DES implantation was associated with a higher rate
of MI and ST during long-term follow-up through 5 years. Incom-
plete stent apposition appears to be one of multiple factors
accounting for the ongoing risk of very late ST after DES implant-
ation, and its prognostic impact requires further investigation.
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